Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy
Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Jun 25, 2014
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how the pancreas responds after a surgery called duodenal pancreatectomy, which involves removing part of the pancreas. The main goal is to understand what factors might predict whether a person will develop diabetes after this surgery. Researchers will study individuals before and after their surgery to see how their bodies manage blood sugar levels and how the remaining pancreatic cells work to produce insulin—the hormone that helps control blood sugar.
To be eligible for the trial, participants need to be scheduled for this surgery and can either have diabetes or not. However, those with chronic diseases or who are on steroid therapy cannot take part. During the study, participants will undergo several tests to evaluate their blood sugar levels and how well their pancreas is functioning. They will also provide samples of their pancreas for further analysis. Overall, this research aims to discover important factors that help the pancreas adapt after surgery, which could lead to better management of diabetes in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • SCHEDULED FOR PANCREATECTOMY
- • NO DIABETIC and DIABETIC
- Exclusion Criteria:
- • CHRONIC DESEASES
- • STEROID THERAPY
About Fondazione Policlinico Universitario Agostino Gemelli Irccs
Fondazione Policlinico Universitario Agostino Gemelli IRCCS is a leading research and healthcare institution based in Rome, Italy, renowned for its commitment to advancing medical science and improving patient care. As a prominent academic medical center affiliated with the Catholic University of the Sacred Heart, it integrates clinical practice, education, and research, fostering innovation in various fields of medicine. The foundation conducts a wide range of clinical trials aimed at developing new therapies and enhancing treatment protocols, with a focus on translational research that bridges the gap between laboratory discoveries and patient care. Its multidisciplinary approach and dedication to high ethical standards position it as a key player in the landscape of clinical research and healthcare improvement in Italy and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rome, Rm, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials